Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: Jan 21, 2010


Bar Harbor BioTechnology this week released its XenoQ assays, which are designed to quantitatate human tumor response in xenograft experiments.

The assays combine quantitative PCR primer design with Bar Harbor's Global Pattern Recognition-analysis methodology, which allows researchers to "accurately measure gene expression and gene copy number variation in human cancer cells without cross-reactivity of other species," the company said in a statement.

Researchers can use the assays to measure how a drug affects a tumor and detect if there is a correlation of dosage to gene copy-number variations found in a patient's cells, the company said.

Bar Harbor has signed an agreement with Lonza to distribute the XenoQ assays. The deal expands a distribution agreement between the firms that began in 2008 that made Lonza the exclusive global distributor of the company's StellArray Gene Expression System, which combines qPCR arrays with the GPR software.

In addition to XenoQ, Lonza will now distribute Bar Harbor's GPR 2.0 and Custom Plate Designer products under the expanded agreement.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.